| P50 | author | Mattias Mattsson | Q85925915 |
| P2093 | author name string | R Rosenquist | |
| | P Baliakas | |
| | K Stamatopoulos | |
| P2860 | cites work | Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines | Q24616084 |
| | Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution | Q26823586 |
| | TP53 mutation and survival in chronic lymphocytic leukemia | Q27851577 |
| | Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia | Q27851685 |
| | Recurrent mutations refine prognosis in chronic lymphocytic leukemia. | Q27853022 |
| | Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment | Q28082086 |
| | Genomic aberrations and survival in chronic lymphocytic leukemia | Q28141442 |
| | Chronic lymphocytic leukemia | Q28236621 |
| | A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia | Q28279141 |
| | Idelalisib and rituximab in relapsed chronic lymphocytic leukemia | Q28306347 |
| | Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia | Q28394721 |
| | Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness | Q29013141 |
| | Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia | Q29620690 |
| | Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data | Q30685440 |
| | Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomes | Q33558148 |
| | Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia | Q33595764 |
| | The clinical significance of patients' sex in chronic lymphocytic leukemia | Q33695983 |
| | Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia | Q33957743 |
| | Richter's transformation in chronic lymphocytic leukemia. | Q34112617 |
| | A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis | Q34282319 |
| | Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia | Q34418874 |
| | Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia | Q34805491 |
| | B-cell clones as early markers for chronic lymphocytic leukemia | Q34943783 |
| | Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations | Q35029461 |
| | Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia | Q35407650 |
| | Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib | Q35450520 |
| | Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia | Q35461949 |
| | NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL | Q35794466 |
| | Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies | Q36083000 |
| | Sex differences in incidence and outcome of chronic lymphocytic leukemia patients | Q36590969 |
| | Evolution and impact of subclonal mutations in chronic lymphocytic leukemia | Q36619124 |
| | Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens | Q37028643 |
| | Validation of a new prognostic index for patients with chronic lymphocytic leukemia | Q37068125 |
| | Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management | Q37552813 |
| | Molecular genetics of high-risk chronic lymphocytic leukemia | Q38065304 |
| | Uncovering the DNA methylome in chronic lymphocytic leukemia | Q38074267 |
| | Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand? | Q38088354 |
| | Richter syndrome | Q38135347 |
| | The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia | Q38473614 |
| | Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study | Q39876261 |
| | Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients | Q43555954 |
| | Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia | Q44904842 |
| | Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. | Q45915574 |
| | Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia | Q47812640 |
| | A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact. | Q50784932 |
| | Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. | Q52621343 |
| | SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. | Q52644149 |
| | Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. | Q53029323 |
| | Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. | Q53596463 |
| | Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. | Q54580268 |
| | Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. | Q54789536 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| | lymphocyte | Q715347 |
| P304 | page(s) | 347-357 | |
| P577 | publication date | 2015-12-28 | |
| P1433 | published in | Journal of Internal Medicine | Q6295387 |
| P1476 | title | Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed? | |
| P478 | volume | 279 | |